Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg upgrades Softcat to 'buy', hikes target price

(Sharecast News) - Analysts at Berenberg upgraded software firm Softcat from 'hold' to 'buy' on Friday and bumped its target price on the stock from 1,600.0p to 1,900.0p as it argued a recent sell-off had provided an attractive entry point. Berenberg said the upgrade was on the basis of Softcat's "continued strong operational performance", as well as its "consistent ability" to beat market expectations and the 15% selloff in its shares over the past two weeks.

The German bank said its view on the company has always been positive. However, it also noted that Softcat's shares now looked "more attractively valued" than at the time of its re-initiation in October 2024, when it traded on a 26.6x one-year forward price-to-earnings ratio and a 3.4% free cash flow yield, relative to our expectation of a 7% FY23/26 earnings per share compound annual growth rate. Today, Berenberg said, Softcat trades on a 22.6x FY26 price-to-earnings relative and a 4.0% free cash flow yield, relative to our expectation of a 10% FY24/26 earnings per share compound annual growth rate.

"Softcat has grown at a double-digit yoy rate since our initiation, with the company delivering multiple profit upgrades. However, the shares are broadly back to where they were at our initiation, following the sell-off on the day of Bytes' AGM trading statement (2 July), meaning they are materially better value on both an absolute and a relative basis," said Berenberg.

"While some of the strong FY25 performance was due to several large deals, performance continues to be broad-based across technology areas and customer segments. In our view, Softcat is the most resilient UK VAR and the one with the best chance of upgrading expectations over the medium term, as it continues to navigate the challenging macroeconomic environment of the past several years admirably."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.